

Canadian Urological Association • Association des urologues du Canada

63rd Annual Meeting • Edmonton, AB • June 22–25, 2008

Sunday, June 22

1050–1150 Welcome Brunch in Exhibit Hall

1150–1300 Official Opening of CUA Annual Meeting
Timothy Wollin, Michael Hobart, Edmonton, AB

1200–1230 CUASF Lecture: Urologic chronic pain syndromes: great hypotheses ruined by good science
J. Curtis Nickel, Kingston, ON

1230–1300 J.O. Metcalfe Lecture: Biochemical and clinical outcomes after radical prostatectomy for clinically localized (cT1/cT2) prostate cancer during the PSA Era
Gary Lieskovsky, Los Angeles, CA

1300–1400 Plenary Session 1

1300–1310 AUA Presidential Address
John Barry, Portland, OR

1310–1340 Royal College Lecture: Malpractice and medico-legal issues for urologists
Claude Martin, Jr., Ottawa, ON

1340–1350 CUA Prize Essay Winner 1

1350–1400 CUA Prize Essay Winner 2

1400–1430 Break in Exhibit Hall

1430–1600 Scientific Session 1: Moderated Video Session Chair: *Brian Blew, Ottawa, ON*

VID-1.01 Complications of ureteroscopy revisited
Sero Andonian, New Hyde Park, NY

VID-1.03 Percutaneous insertion of a stent in laparoscopic pyeloplasty: a new technique
Ahmed Al Zahrani, Montréal, QC

VID-1.04 Urethral diverticulectomy in the female
Anne K. Pelletier Cameron, Ann Arbor, MI

VID-1.05 Distal urethroplasty in a female with a mid-urethral stricture
Anne K. Pelletier Cameron, Ann Arbor, MI

VID-1.06 Laparoscopic partial nephrectomy for a complex hilar tumour: surgical technique
Michael Pianezza, Edmonton, AB

VID-1.07 Vesico-vaginal fistula laparoscopic repair
Alessandro Volpe, Orbassano, Italy

VID-1.08 Laparoscopic transvesical ureteral reimplantation for obstructive megaureter
Alessandro Volpe, Orbassano, Italy

VID-1.09 Important findings on fluoroscopy during videourodynamics: a teaching file
Anne K. Pelletier Cameron, Ann Arbor, MI

VID-1.10 Percutaneous renal surgery: how to minimize bleeding
Sero Andonian, New Hyde Park, NY

Unmoderated Videos

UVID-1.02 Digital ureteroscopy: the next step
Sero Andonian, New Hyde Park, NY

UVID-1.02 The accordion: a new device to prevent stone migration during ureteroscopic lithotripsy
This paper has been awarded a 5-star distinction
Ben Chew, Vancouver, BC

Moderated Posters Session 1: Oncology – Prostate: Diagnosis and Natural History

Chairs: *Gary Lieskovsky, Los Angeles, CA; Laurence Klotz, Toronto, ON*

MP-1.01 Clinical application of chromosome 8q24 SNPs in prostate cancer diagnosis
This paper has been awarded a 5-star distinction
Sanoj Punnen, Toronto, ON

MP-1.02 Long-chain omega-3 fatty acids, COX2 gene polymorphism, and aggressive prostate cancer
This paper has been awarded a 5-star distinction
Vincent Fradet, San Francisco, CA

MP-1.03 Nomogram evaluation of the PCA3 molecular urine test for prostate cancer detection
Robert Nam, Toronto, ON

MP-1.04 Active surveillance for favorable risk prostate cancer: update of the Sunnybrook experience
This paper has been awarded a 5-star distinction
Laurence Klotz, Toronto, ON

MP-1.05 The impact of dietary factors on prostate cancer progression in patients on active surveillance
Lysanne Campeau, Montréal, QC

MP-1.06 Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathological features
Naeem Bhojani, Montréal, QC

MP-1.07 Nonsteroidal anti-inflammatory drug use is associated with decreased prostate cancer mortality
Salah Mahmud, Montréal, QC

MP-1.08 Role of magnetic resonance spectroscopic imaging in patients diagnosed with prostate cancer managed with active surveillance
Vincent Fradet, San Francisco, CA

MP-1.09 External-beam radiation therapy increases the rate of secondary malignancies relative to radical prostatectomy in men with prostate cancer
Naeem Bhojani, Montréal, QC

MP-1.10 The relationship between prostate tumour density and pathologic and clinical outcomes
Gaayana Raju, Ottawa, ON

- MP-1.11 External validation of the updated Partin tables in a cohort of North American men
Naeem Bhojani, Montréal, QC
- MP-1.12 The effect of androgen deprivation therapy on the rate of subsequent non-cancer morbidities
Claudio Jeldres, Montréal, QC
- MP-1.13 Intake of a healthy diet pattern and health related quality of life in patients diagnosed with prostate cancer
Vincent Fradet, San Francisco, CA
- MP-1.14 Repeat biopsy for ultrasound-guided prostate biopsy system
Yujun Guo, Grass Valley, CA
- Moderated Posters Session 2: Training/UTI/Sexual Function**
Chairs: *Derek Bochinski, Edmonton, AB; J. Curtis Nickel, Kingston, ON*
- MP-2.01 Closure v. nonclosure of buccal mucosal graft harvest site: a randomized controlled trial
This paper has been awarded a 5-star distinction
Blair St. Martin, Edmonton, AB
- MP-2.02 Accounting for attrition rates and causes of intercavernosal injection therapy (ICI) in patients with erectile dysfunction (ED)
Shubha De, Halifax, NS
- MP-2.03 Quality of life assessment after urethral reconstruction
Chasta-Dawne Bacsu, Edmonton, AB
- MP-2.04 Bacterial adhesion and viability to 5 commercially available stents
Dirk Lange, Vancouver, AB
- MP-2.05 Uropathogen stimulated cytokine expression in bladder and kidney cell culture and the effects of triclosan
Ben Chew, Vancouver, BC
- MP-2.06 Staged urethral reconstruction using buccal mucosal grafts: an analysis of complications and success rates
Conrad Maciejewski, Edmonton, AB
- MP-2.07 Long-distance tele-mentoring: future in training laparoscopic radical prostatectomy?
Livia Lee, London, ON
- MP-2.08 Uropedia: an online urology community resource for urological trainees
Christopher Ngan, Vancouver, BC
- MP-2.09 Quality assurance for radical cystectomy morbidity and mortality
Venu Chalasani, London, ON
- MP-2.10 Early induction of erectile dysfunction by angiotensin II in the rat
This paper has been awarded a 5-star distinction
Frédéric Mampouma, Montréal, QC
- MP-2.11 Developing a prognostic tool for Peyronie's disease: validation of a percutaneous aspiration technique
Trustin Domes, London, ON
- MP-2.12 Endothelial effects of chronic sildenafil use among diabetic men
Gerald Brock, London, ON
- MP-2.13 Intracorporal pressure measurement as an index of erectile function: is there a better way?
This paper has been awarded a 5-star distinction
Petar Erdeljan, London, ON
- MP-2.14 Erectile dysfunction: what motivates men to finally seek treatment?
Stephen Scott Steele, Kingston, ON
- MP-2.15 Fellow or foe: the impact of fellowship training programs on the education urology residents in the USA and Canada
Rose Khavari, Houston, TX
- Moderated Posters Session 3: General Oncology/Penile and Testis**
Chairs: *Michael Jewett, Toronto, ON; Niels Jacobsen, Edmonton, AB*
- MP-3.01 EGFR over-expression in squamous cell carcinoma of the penis
Nathan Lavens, Halifax, NS
- MP-3.02 Outcome of surgical treatment of patients with upper versus lower urinary tract urothelial carcinoma: stage by stage comparison
This paper has been awarded a 5-star distinction
Sabri Moussa, Montréal, QC
- MP-3.03 Primary retroperitoneal lymph node dissection for clinical low stage nonseminomatous germ cell testicular tumours
David Kakiashvili, Toronto, ON
- MP-3.04 Post-chemotherapy retroperitoneal lymph node dissection of residual retroperitoneal mass for testicular germ cell tumours: is bilateral template necessary?
This paper has been awarded a 5-star distinction
David Kakiashvili, Toronto, ON
- MP-3.05 Management of post-radical prostatectomy complete bladder neck occlusion
Sender Herschorn, Toronto, ON
- MP-3.06 Testicular cancer patient participation in tissue banking: the Alberta Research Tumour Bank experience
Edith Pituskin, Edmonton, AB
- MP-3.07 Kidney-sparing management of upper urinary tract transitional cell carcinoma
Sabri Moussa, Montréal, QC
- MP-3.08 Comparison of open and laparoscopic nephroureterectomies for management of upper urinary tract transitional cell carcinoma
Muhammad Zeeshan Aslam, Wakefield, UK
- MP-3.09 Comparison of epidural and intravenous patient controlled analgesia in patients undergoing radical cystectomy
Paul Toren, Toronto, ON
- 1600–1720 Plenary Session 2: Renal Oncology**
- 1600–1630 State-of-the-Art Lecture: Update on the use of targeted therapy in the treatment of advanced renal cell carcinoma
Lori Wood, Halifax, NS
- 1630–1720 Educational Forum 1: Renal Oncology Surgery for RCC: current trends
Moderator: *Darrel Drachenberg, Winnipeg, MB*

Panel: <i>Anil Kapoor</i> , Hamilton, ON; <i>Bryan Donnelly</i> , Calgary, AB; <i>Michael Hobart</i> , Edmonton, AB		MP-4.05	Outcome of capsular invasion in clinically localized renal tumour <i>This paper has been awarded a 5-star distinction</i> <i>Darwin Lim</i> , London, ON
1800–2100	Welcome Reception		
Monday, June 23			
0700–0750	Sponsored Symposium 1 Sponsored by Merck Frosst	MP-4.06	Increasing tumour size is associated with higher rates of high Fuhrman nuclear grade in patients with renal cell carcinoma <i>Claudio Jeldres</i> , Montréal, QC
0800–0850	Sponsored Symposium 2 Sponsored by Bayer HealthCare	MP-4.07	Gender differences in renal cell cancer patients <i>Claudio Jeldres</i> , Montréal, QC
0900–0925	Break in Exhibit Hall	MP-4.08	T4 stage renal cell carcinoma without any evidence of metastatic disease have similar cancer-specific survival rates to those with nodal metastasis after radical nephrectomy <i>This paper has been awarded a 5-star distinction</i> <i>Claudio Jeldres</i> , Montréal, QC
0930–1130	Plenary Session 3: Stones/Endourology		
0930–1000	Sunday Meeting Highlights		
1000–1030	State-of-the-Art Lecture: New thoughts on the etiology of urinary stone disease <i>Marshall Stoller</i> , San Francisco, CA	MP-4.09	Pathological upstaging in clinically localized renal tumour: is it a concern? <i>Darwin Lim</i> , London, ON
1030–1120	Educational Forum 2: Endourology Diagnosis and management of UPJ obstruction Moderator: <i>Ryan Paterson</i> , Vancouver, BC Panel: <i>Marshall Stoller</i> , San Francisco, CA; <i>John Duchinski</i> , Calgary, AB; <i>J. Paul Whelan</i> , Hamilton, ON	MP-4.10	Diagnostic yield of image-guided fine needle aspiration of solid renal masses <i>Sero Andonian</i> , New Hyde Park, NY
1130–1230	Lunch in Exhibit Hall	MP-4.11	A contemporary analysis of the utility of liver enzymes for the detection of hepatic metastases in renal cell carcinoma <i>Kamal Mattar</i> , Toronto, ON
1230–1400	Plenary Session 4: Incontinence and Voiding Dysfunction	MP-4.12	A nomogram for prediction of early renal cancer-specific mortality in patients with nodal metastases <i>Claudio Jeldres</i> , Montréal, QC
1230–1300	State-of-the-Art Lecture: Past and future of mid-urethral slings for stress urinary incontinence <i>J. Christian Winters</i> , New Orleans, LA	MP-4.13	Cryotherapy for small renal masses <i>Venu Chalasani</i> , London, ON
1305–1355	Educational Forum 3: Incontinence and voiding dysfunction Changing and emerging technologies in pelvic health Moderator: <i>Kevin Carlson</i> , Calgary, AB	MP-4.14	A nomogram for prediction of renal insufficiency development after nephron-sparing surgery for renal cancer <i>Claudio Jeldres</i> , Montréal, QC
1230–1400	Scientific Session 2	MP-4.15	Perioperative morbidity in patients treated with targeted therapy for metastatic renal cell carcinoma <i>Sultan Alkhateeb</i> , Toronto, ON
	Moderated Posters Session 4: Oncology — Kidney/Ureter Chairs: <i>Stephen Pautler</i> , London, ON; <i>Ricardo Rendon</i> , Halifax, NS		Moderated Posters Session 5: Pediatric Urology Chairs: <i>Richard Rink</i> , Indianapolis, IN; <i>Darcie Kiddoo</i> , Edmonton, AB
MP-4.01	Partial v. radical nephrectomy in patients with adverse clinical and pathological renal cell carcinoma characteristics: a matched analysis <i>Claudio Jeldres</i> , Montréal, QC	MP-5.01	Tissue engineering of a genitourinary tubular tissue graft resistant to suturing and to high internal pressures <i>This paper has been awarded a 5-star distinction</i> <i>Martine Magnan</i> , Québec, QC
MP-4.02	A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma: a multi-institutional validation of a cancer-specific survival nomogram <i>Claudio Jeldres</i> , Montréal, QC	MP-5.02	Urinary TGFB1 concentration in the first 3 months of life can predict surgery in newborns with unilateral hydronephrosis <i>Fayez Almodhen</i> , Montréal, QC
MP-4.03 P	Predicting development of chronic renal impairment after nephrectomy for malignancy <i>Darwin Lim</i> , London, ON	MP-5.03	Outcome analysis of different pyeloplasty approaches in an age-matched pediatric cohort <i>Luis H.P. Braga</i> , Toronto, ON
MP-4.04	Then and now: the effect of tyrosine kinase inhibitors on survival in patients with metastatic renal cell carcinoma in Alberta, Canada <i>This paper has been awarded a 5-star distinction</i> <i>Peter Venner</i> , Edmonton, AB	MP-5.04	Prospective open-label double anticholinergic therapy for refractory hyperreflexic bladder in children <i>Stéphane Bolduc</i> , Québec, QC

MP-5.05	Urodynamic and histologic changes over time in an animal model of bladder outlet obstruction <i>Peter Metcalfe, Edmonton, AB</i>	MP-6.05	Frequency of cyclooxygenase-2 expression is increased in non-muscle invasive bladder tumours at higher risk of recurrence <i>This paper has been awarded a 5-star distinction</i> <i>Anis Aziz, Québec, QC</i>
MP-5.06	Fowler-Stephens orchiopexy: is staging beneficial? A systematic review <i>This paper has been awarded a 5-star distinction</i> <i>R. Elyas, Ottawa, ON</i>	MP-6.06	Inter-related effects of androgens, fatty acids and oxidative stress in prostate cancer: a mechanistic support for prevention strategies <i>This paper has been awarded a 5-star distinction</i> <i>Jehonathan Pinthus, Hamilton, ON</i>
MP-5.07	Role of calyx to parenchyma ratio in diagnosis and follow-up of unilateral antenatal hydronephrosis <i>Fayez Almodhen, Montréal, QC</i>	MP-6.07	Micronutrient supplementation precludes tumour progression by elevating the endogenous inhibitor of angiogenesis, platelet factor-4 (PF-4), in the Lady mouse <i>Laurence Klotz, Toronto, ON</i>
MP-5.08	Identifying risk factors of hypospadias that predict severity of malformation <i>William Carlson, Halifax, NS</i>	MP-6.08	NADPH oxidases as a potential target for prostate cancer radio sensitization <i>Jehonathan Pinthus, Hamilton, ON</i>
MP-5.09	Single-surgeon evolution of maneuvers impacting fistula formation in tubularized incised plate hypospadias <i>This paper has been awarded a 5-star distinction</i> <i>Luis H.P. Braga, Toronto, ON</i>	MP-6.09	Application of electrochemical principles in the treatment of localized prostate cancer <i>Bimal Bhindi, Montréal, QC</i>
MP-5.10	Urine cytology in neuropathic and augmented bladders <i>Peter Metcalfe, Edmonton, AB</i>	MP-6.10	IKK ϵ monitors IL-6 deregulation in prostate cancer cells <i>Benjamin Péant, Montréal, QC</i>
MP-5.11	Comprehensive analysis of the clinical and urodynamic outcomes of spinal cord un-tethering <i>Ahmed Al Zahrani, Montréal, QC</i>	MP-6.11	PDE inhibition as a chemotherapeutic adjuvant for prostate cancer <i>D. Robert Siemens, Kingston, ON</i>
MP-5.12	Development of a symptom score for dysfunctional elimination syndrome <i>Kourosh Afshar, Vancouver, BC</i>	MP-6.12	Intra-arterial injection of lipophilic photosensitizer for photodynamic therapy of the canine prostate <i>Ronald Moore, Edmonton, AB</i>
MP-5.13	Selective ablation of intestinal mucosa using laser photodynamic therapy with 5-aminolaevulinic acid: an experimental study in pigs <i>Luis H.P. Braga, Toronto, ON</i>	MP-6.13	Androgen regulated immunosuppression in prostate cancer through arginase expression <i>Philippe Olivier Gannon, Montréal, QC</i>
MP-5.14	Outcome analysis of peritoneal dialysis catheter placement in children: impact of malfunction and need for surgical revision <i>Yaser El-Hout, Toronto, ON</i>	MP-6.14	Role of angiotensin II receptors in prostate cancer <i>Maude Carmel, Sherbrooke, QC</i>
Moderated Poster Session 6: Oncology: Basic Science Chairs: <i>Rob Siemens, Kingston, ON; Ronald Moore, Edmonton, AB</i>		MP-6.15	Tumour suppressive effects of adiponectin in renal cell carcinoma: in vitro studies <i>Nir Kleinmann, Hamilton, ON</i>
MP-6.01	Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin <i>Alan So, Vancouver, BC</i>	1400–1430	Break in Exhibit Hall
MP-6.02	Intravesically administered antisense oligonucleotides targeting HSP27 inhibit the growth of nonmuscle-invasive bladder cancer <i>Alan So, Vancouver BC</i>	1430–1600	Plenary Session 5: Pediatric Urology 1430–1500 State-of-the-Art Lecture: Complications of catheterizable channels <i>Richard Rink, Indianapolis, IN</i>
MP-6.03	Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer <i>Alan So, Vancouver BC</i>	1500–1550	Educational Forum 4: Pediatric urology Complications of augmented bladders Moderator: <i>Karen Psooy, Winnipeg, MB</i>
MP-6.04	Comparison of bladder cancer cell apoptosis induced by bovine alpha-lactalbumine complex or tumour necrosis factor-related apoptosis-inducing ligand <i>This paper has been awarded a 5-star distinction</i> <i>Jimmy Xiao, Edmonton, AB</i>	1600–1730	Scientific Session 3 Moderated Posters Session 7: Stones/Endourology Chairs: <i>Marshall Stoller, San Francisco, CA; Ben Chew, Vancouver, BC</i>
		MP-7.01	What is the appropriate length of ureteral access sheath for flexible ureteroscopy? <i>This paper has been awarded a 5-star distinction</i> <i>Laura Chang Kit, Vancouver, BC</i>

MP-7.02	Coherent scatter computed tomography for the analysis of urinary calculi: preliminary results of a prospective trial <i>This paper has been awarded a 5-star distinction</i> Geoffrey Wignall, London, ON	MP-8.02	The prognostic significance of capsular incision at radical prostatectomy <i>This paper has been awarded a 5-star distinction</i> Raju Gaayana, Ottawa, ON
MP-7.03	In vitro comparison of 1.5Fr and 2.2F four wire nitinol stone baskets Trevor Schuler, Toronto, ON	MP-8.03	Does surgical experience affect urinary incontinence rates after laparoscopic radical prostatectomy? Matthew Hyndman, Edmonton, AB
MP-7.04	Stones lodge at 3 sites of anatomic narrowing in the ureter: clinical fact or fiction? Trevor Schuler, Toronto, ON	MP-8.04	Changes in health-related quality of life and health values over 12 months after radical prostatectomy Jennifer Ku, Toronto, ON
MP-7.05	Cryotherapy of the nephrostomy tract decreases the risk of hemorrhage in percutaneous renal surgery <i>This paper has been awarded a 5-star distinction</i> Sero Andonian, New Hyde Park, NY	MP-8.05	Low but detectable prostate specific antigen post-radical prostatectomy in the era of the ultrasensitive assay David Rebuck, Edmonton, AB
MP-7.06	Effect of holmium laser settings on stone fragmentation in vitro Trevor Schuler, Toronto, ON	MP-8.06	Treatment of localized prostate cancer with high intensity focused ultrasound (HIFU): 18 months results of the Canadian experience Mohamed Soliman Elkelini, Toronto, ON
MP-7.07	Bidirectional transport of oxalate in the colon: a potential mechanism to reduce hyperoxalemia? Dirk Lange, Vancouver, BC	MP-8.07	Phase II study of treatment with 5 alpha reductase inhibitors in low-risk prostate cancer Jerome Lévesque, Québec, QC
MP-7.08	Utilization patterns of shockwave lithotripsy (SWL) at a high volume regional referral centre Trevor Schuler, Toronto, ON	MP-8.08	Improving treatment results for localized prostate cancer using combined single fraction HDR-brachytherapy and short-course external beam radiation therapy Fabio Cury, Montréal, QC
MP-7.09	A review of the indications for cancellation of shockwave lithotripsy (SWL) at a high-volume centre: strategies to reduce the cancellation rate Daniela Ghiculete, Toronto, ON	MP-8.09	Antibiotic prophylaxis during Foley catheter removal after laparoscopic radical prostatectomy Matthew Hyndman, Edmonton, AB
MP-7.10	Differences in the metabolic profile of diabetic and non-diabetic uric acid stone formers Reem Al-Bareeq, London, ON	MP-8.10	Outcome following radical prostatectomy in the treatment of high-risk prostate cancer Aaron Clark, Ottawa, ON
MP-7.11	Effects of novel coatings inspired by marine mussels on ureteral stent encrustation and uropathogen adherence in vivo Geoffrey Wignall, London, ON	MP-8.11	Robotic radical prostatectomy: development of the first program in the province of Quebec Sabri Moussa, Montréal, QC
MP-7.12	Introduction of a novel biodegradable ureteral stent Ben H. Chew, Vancouver, BC	MP-8.12	Incidence of positive surgical margins in radical prostate specimens at a community hospital Todd Webster, Owen Sound, ON
MP-7.13	Determining composition of urinary calculi using dual energy computed tomography (DECT) Arash Eftekhari, Vancouver, BC	MP-8.13	Robotic-assisted laparoscopic radical prostatectomy at the University of Alberta: analysis of outcomes and learning curves of the initial 40 cases Michael Pianezza, Edmonton, AB
MP-7.14	Bleeding complications of percutaneous nephrolithotomy from a single teaching centre Reza Hamidzadeh, Vancouver, BC	MP-8.14	A phase II neoadjuvant study of OGX-011: a 2'-methoxyethyl phosphorothioate antisense to clusterin, in patients with prostate cancer prior to prostatectomy Kim Chi, Vancouver, BC
MP-7.15	A comparison of ureteroscopic laser lithotripsy in obese and normal weight patients Christopher John Zappavigna, Vancouver, BC	MP-8.15	A phase II randomized CUOG study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer (HRPC) who relapsed on or within 6 months of 1st-line docetaxel therapy <i>This paper has been awarded a 5-star distinction</i> Fred Saad, Montréal, QC
Moderated Posters Session 8: Oncology — Prostate: Localized Disease Chairs: Fred Saad, Montréal, QC; Robert Nam, Toronto, ON			
MP-8.01	Radical retropubic prostatectomy for high-risk prostate cancer: the Vancouver experience <i>This paper has been awarded a 5-star distinction</i> Jeremy Grummet, Vancouver, BC	MP-8.16	Normalization of NTX levels correlate with significantly increased clinical benefits in patients with bone metastases secondary to prostate cancer Fred Saad, Montréal, QC

Moderated Poster Session 9: Oncology — Bladder/Urinary Diversion

Chairs: *Jonathan Izawa*, London, ON; *Alan So*, Vancouver, BC

- MP-9.01 Comparison between open and laparoscopic radical cystectomy for bladder cancer: results from the Alberta Urology Institute radical cystectomy database
Adrian Fairey, Edmonton, AB
- MP-9.02 Determination of the outcomes of bladder cancer patients with “unsatisfactory” urine cytology
Michael Ordon, Toronto, ON
- MP-9.03 Update on delay to radical cystectomy in Quebec
Nader Fahmy, Montréal, QC
- MP-9.04 Impact of wait times for cystectomy on overall survival in Ontario: a population-based study
This paper has been awarded a 5-star distinction
Girish Kulkarni, Toronto, ON
- MP-9.05 Statins and non-muscle invasive bladder cancer evolution: a population-based study
This paper has been awarded a 5-star distinction
Vincent Fradet, San Francisco, CA
- MP-9.06 Outcomes of radical cystectomy for bladder cancer: results from the Alberta Urology Institute radical cystectomy database
This paper has been awarded a 5-star distinction
Adrian Fairey, Edmonton, AB
- MP-9.07 MSH2 mutations and bladder cancer risk: family members of hereditary nonpolyposis colorectal cancer (HNPCC) patients with MSH2 mutations are at increased risk not only for upper urinary tract transitional cell carcinoma (TCC) but also bladder cancer
Alexandre Zlotta, Toronto, ON
- MP-9.08 Contemporary outcome of patients who had an aborted cystectomy due to unresectable bladder cancer
Faysal Yafi, Montréal, QC
- MP-9.09 The impact of cystectomy hospital and surgeon volume on postoperative and overall mortality in Ontario: a population-based study
Girish Kulkarni, Toronto, ON
- MP-9.10 Provider volume and long-term outcomes for radical cystectomy: an assessment of underlying structure and process of care measures
Girish Kulkarni, Toronto, ON
- MP-9.11 Prognosis of bladder cancer: difference between primary muscle invasive and recurrent or progressive non-muscle invasive urothelial tumours
Fadi Kamal, Ottawa, ON
- MP-9.12 Long-term results of BCG in the treatment of T1G3 bladder cancer
David Kakiashvili, Toronto, ON
- MP-9.13 Trans-abdominal ultrasound for the detection of bladder cancer: How reliable is it?
Vincent Fradet, San Francisco, CA

- MP-9.14 A conditional nomogram for prediction of early recurrence of bladder cancer after radical cystectomy
Claudio Jeldres, Montréal, QC

- MP-9.15 Salvage radical cystectomy post chemoradiotherapy: the Ottawa experience
Joshua D. Wiesenthal, Ottawa, ON

- 1900–2300 CUA Fun Night at Fort Edmonton Park

Tuesday, June 24

- 0700–0750 Sponsored Symposium 3
Sponsored by GlaxoSmithKline

0800–0920 Plenary Session 6: Bladder Oncology

- 0800–0825 Monday Meeting Highlights

0830–0920 Educational Forum 5: Bladder oncology Multidisciplinary treatment approach to invasive bladder cancer

Moderator: *Yves Fradet*, Québec, QC; *Armen Aprikian*, Montréal, QC; *Mack Roach, III*, San Francisco, CA; *Kim Chi*, Vancouver, BC

- 0930–1000 Break in Exhibit Hall

1000–1200 Plenary Session 7: Live Surgery
Robotic Radical Prostatectomy (Theatre 1)
Tom Ahlering, Irvine, CA

- Open radical Prostatectomy (Theatre 2)
Gary Lieskovsky, Los Angeles, CA

Wednesday, June 25

- 0700–0750 Sponsored Symposium 4
Sponsored by Sanofi-Aventis

0800–1000 Plenary Session 8: BPH/LUTS and Testis Cancer

- 0800–0815 Tuesday Meeting Highlights

- 0815–0825 CUA Historical Lecture — A look into the void: a brief history of the diagnostic and therapeutic qualities of urine
State-of-the-Art Lecture: A critical appraisal of minimally invasive treatments for BPH/LUTS
Claus Roehrborn, Dallas, TX

0905–0955 Educational Forum 6: Testis cancer Current management of NSGCT

- 1000–1030 Break in Exhibit Hall

1030–1200 Scientific Session 4**Moderated Posters Session 10: LUTS/Incontinence/Voiding Dysfunction**

Chairs: *Klaus Roehrborn*, Dallas, TX; *J. Christian Winters*, New Orleans, LA

- MP-10.01 "Add-on" tolterodine extended release improves over-active bladder symptoms in men receiving alpha-blocker therapy
This paper has been awarded a 5-star distinction
Sender Herschorn, Toronto, ON
- MP-10.02 A PSA-activated protoxin (prx302) administered transperineally to men with symptomatic benign prostatic hyperplasia is well tolerated and exhibits signs of activity
Peter Pommerville, Victoria, BC
- MP-10.03 Body mass index and its association with genito-urinary disorders in men undergoing prostate cancer screening
Naeem Bhojani, Montréal, QC
- MP-10.04 A comparison of perioperative factors between men with and without urinary retention at the time of transurethral resection of the prostate
David Rebuck, Edmonton, AB
- MP-10.05 Laparoscopic transcapsular simple prostatectomy (Millin): our experience after 50 cases
Alessandro Volpe, Orbassano, Italy
- MP-10.06 An evaluation of patient and physician satisfaction with controlled-release oxybutynin 15mg as a one-step daily dose in elderly and non-elderly patients with overactive bladder: results of the STOP study
Catherine Flood, Edmonton, AB
- MP-10.07 Nocturia in the elderly: age differences in functional bladder capacity as observed on cystometrogram
This paper has been awarded a 5-star distinction
Stephen Scott Steele, Kingston, ON
- MP-10.08 Urodynamic changes following AdVance male sling insertion
Timothy Davies, Norfolk, VA
- MP-10.09 A modified approach for patient selection in sacral nerve neuromodulation
Béchir Hage, Sherbrooke, QC
- MP-10.10 Sacral nerve stimulation in Western Canada: a summary of the experience at our institution
Gregory Roberts, Calgary, AB
- MP-10.11 The use of botulinum toxin A in patients with neurogenic detrusor overactivity: preliminary results from a Canadian multicentre randomized trial
This paper has been awarded a 5-star distinction
Sender Herschorn, Toronto, ON
- MP-10.12 Bulbous urethral reconstruction using buccal mucosa with a dorsal onlay technique
Keith Rourke, Edmonton, AB
- MP-10.13 Outcomes of concomitant surgery for stress urinary incontinence and pelvic organ prolapse
Audrey Wang, Toronto, ON
- MP-10.14 Interstitial cystitis/painful bladder syndrome and sexual abuse
Abhishek Seth, Vancouver, BC
- MP-10.15 Long-term outcomes of the treatment of male stress urinary incontinence with polydimethylsiloxane following spinal cord injury
Pratik MS Gurung, London, UK
- Moderated Poster Session 11: MIS/Transplantation**
Chairs: Alain Duclos, Montréal, QC; Chris Ngan, Vancouver, BC
- MP-11.01 Real-time quantification of renal ischemia using in vivo expression of p-selectin
Sero Andonian, New Hyde Park, NY
- MP-11.02 Predictors of health related quality of life (HRQOL) recovery following laparoscopic radical, donor and simple nephrectomy
This paper has been awarded a 5-star distinction
Trevor Schuler, Toronto, ON
- MP-11.03 Single port laparoscopic renal surgery: the Cleveland clinic experience
This paper has been awarded a 5-star distinction
Raj Goel, Cleveland, OH
- MP-11.04 Single port laparoscopic pelvic surgery: a new horizon in urology
Raj Goel, Cleveland, OH
- MP-11.05 Percutaneous renal cryoablation: early results from a prospective database
Charles Metcalfe, Calgary, AB
- MP-11.06 Robotic pyeloplasty: long-term follow-up of first Canadian experience
Petar Erdeljan, London, ON
- MP-11.07 Retroperitoneal laparoscopic partial nephrectomy: the Québec City experience
George Adamo, Québec, QC
- MP-11.08 Effects of warm ischemia time on differential renal function after laparoscopic partial nephrectomies: the Laval University experience
Frédéric Pouliot, Québec, QC
- MP-11.09 Left transperitoneal laparoscopic pyeloplasty with transmesocolic access to the uretero-pelvic junction: description of the technique and results with a one-year minimum follow-up
Alessandro Volpe, Orbassano, Italy
- MP-11.10 Outcomes of kidney transplantation from donors after cardiocirculatory death: the Ontario experience
Jeff Warren, London, ON
- MP-11.11 Donor preconditioning with CORM-2 protects against ischemia-reperfusion injury in a murine kidney transplant model
Jeff Warren, London, ON
- MP-11.12 Living unrelated (commercial) renal transplantation: a single Canadian centre experience
This paper has been awarded a 5-star distinction
Niki Kanaroglou, Hamilton, ON
- MP-11.13 Laparoscopy, dorsal lumbotomy, and flank incision in live donor nephrectomy: comparison of donor outcomes
Dinesh Samarasekera, Vancouver, BC
- MP-11.14 Long-term health related quality of life (HRQOL) following laparoscopic and open donor nephrectomy
Trevor Schuler, Toronto, ON

MP-11.15 Radiopaque contrast administration during deceased donor evaluation: effects on renal transplant outcomes
Amjad Al-Waal, Vancouver, BC

Moderated Posters Session 12: Oncology — Prostate: Advanced Disease

Chairs: *Tom Ahlering, Irvine, CA; Kim Chi, Vancouver, BC*

MP-12.01 A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel
Kim Chi, Vancouver, BC

MP-12.02 One-year, North American multi-center, randomized dose-finding study of degarelix, a gonadotrophin-releasing hormone (gnrh) receptor blocker, in patients with prostate cancer
Peter J. Pommerville, Aventura, FL

MP-12.03 A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy naive hormone refractory prostate cancer (HRPC)
This paper has been awarded a 5-star distinction
Emma Beardsley, Vancouver, BC

MP-12.04 Intermittent androgen deprivation therapy (ADT) in the management of hormone independent prostate cancer (HIPC): results of a multi-institutional randomized prospective clinical trial
Ricardo A. Rendon, Halifax, NS

MP-12.05 Added-value of SPECT-TC to ProstaScint imaging for biochemical failure following definitive local prostate cancer therapy
Joseph Chin, London, ON

MP-12.06 Prediction of survival benefit from docetaxel chemotherapy with PSA response and PSA half-life in men with hormone refractory prostate cancer
Mikael Hanninen, Edmonton, AB

MP-12.07 Low usage of docetaxel among patients with metastatic hormone refractory prostate cancer (HRPC): a population-based analysis
Emma Beardsley, Vancouver, BC

MP-12.8 Treatment outcome of immediate versus delayed hormone therapy in patients with lymph node metastases following radical prostatectomy
Michel Hugues Lebel, Québec, QC

1400–1630 Plenary Session 9: Contemporary Management of Localized Prostate Cancer

1400–1430 State-of-the-Art Lecture: The ultimate MIS procedure: RT for prostate cancer
Mack Roach, III, San Francisco, CA

1430–1630 Panel Discussion: Radical prostatectomy — Is there a best procedure?
Moderator: *David Mador, Edmonton, AB*

1435–1455 “Why I switched to robotic from open”
Tom Ahlering, Irvine, CA

1455–1515 “Why I switched to robotic from lap”
Richard Gaston, Bordeaux, France

1515–1535 “Why I do lap only”
Philippe Arjane, Montréal, QC

1535–1555 “Why I do open only”
Gary Lieskovsky, Los Angeles, CA

Unmoderated Posters

Unmoderated Poster Session 1

Sunday, June 22, 1045–1630, Exhibit Hall

Unmoderated Poster Session 2

Monday, June 23, 0900–1630, Exhibit Hall

Unmoderated Poster Session 3

Tuesday, June 24, 0900–1300, Exhibit Hall

1630 Adjournment

1900–2300 President’s Banquet